Search academic texts

Information × Registration Number 0220U101877, 0119U102525 , R & D reports Title Novel approaches for treatment of disseminated drug-resistant tumors using anguclycline antibiotic landomycin A complexed with poly(2)-oxazoline nanocarrier popup.stage_title Head Panchuk Rostyslav R., Доктор біологічних наук Registration Date 27-02-2020 Organization Institute of Cell Biology popup.description2  For the first time the unique ability of landomycin A to form adducts with thiol-containing compounds in malignant cells has been identified, and the key role of this phenomenon in circumvention of the acquired cancer drug resistance by LA is demonstrated. Landomycin A induces rapid apoptosis in target cells, accompanied by early activation of effector caspase-7 and cleavage of its substrate, the PARP-1 protein, at 1 hour of LA action. At this timepoint no signs of depolarization of mitochondria were observed, as well as absence of cleaved forms of caspases involved in the mitochondrial pathway of apoptosis. This specific action of landomycin A was identical towards tumor cells, that were drug-sensitive and their chemotherapy-resistant sublines, and is important in the treatment of multiple drug resistance by landomycins. Landomycin A is a weak inducer of immunogenic cell death, unlike other known drug doxorubicin. At the same time, LA exhibits a higher therapeutic potential in vivo than doxorubicin towards murine B16 melanoma model. This indicates on significant prospects for the use of landomycin A in clinical practice. Product Description popup.authors Kashchak Nataliya I. Kozak Yuliya S. Skorokhyd Nadiya R. popup.nrat_date 2020-04-02 Close